Blueprint Medicines Corp · Q4 2021 earnings

Briefing

Blueprint Medicines reported Q4 2021 earnings with a focus on AYVAKIT and total revenues for the year, along with forward-looking statements for 2022.

Blueprint Medicines reported its Q4 and full year 2021 financial results, highlighting the achievement of $53.0 million in AYVAKIT net product revenues and $180.1 million in total revenues for the full year 2021. The company anticipates significant year-over-year product revenue growth in 2022 and is expanding its research platform.

• Achieved $53.0 million in AYVAKIT net product revenues and $180.1 million in total revenues in 2021.
• Anticipate approximately $115 million to $130 million in AYVAKIT net product revenues and $180 million to $200 million in total revenues in 2022.
• Multiple abstracts accepted for presentation at the AACR annual meeting including initial Phase 1/2 SYMPHONY trial dose escalation data for BLU-945 in EGFR-driven NSCLC.
• IND applications cleared by FDA for BLU-451 in EGFR exon 20-positive NSCLC and BLU-222 in cyclin E-CDK2 aberrant cancers; on track to initiate Phase 1/2 studies for both programs in Q1 2022.

Headline financials

Revenue & EPS history

Blueprint Medicines anticipates approximately $180M to $200M in total revenues in 2022, including approximately $115M to $130M in AYVAKIT net product revenues. The company expects that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.